Tags : Kisqali (ribociclib)

Novartis Reports Results of Kisqali (ribociclib) + Endocrine Therapy in

Vartika Singh December 11, 2018

Shots: The P-III MONALEESA trials (MONALEESA-2, 3,7) involved assessing of Kisqali (ribociclib) + endocrine therapy vs endocrine therapy alone in patients with visceral metastases in pre, peri- and postmenopausal women […]readmore

Tags : Kisqali (ribociclib)

Novartis Reports Results of Kisqali (ribociclib) + Endocrine Therapy in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Kisqali (ribociclib)

Novartis Reports Results of Kisqali (ribociclib) + Endocrine Therapy in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company